MED Stock Overview
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$142.03|
|52 Week High||US$239.56|
|52 Week Low||US$125.18|
|1 Month Change||-16.33%|
|3 Month Change||-12.99%|
|1 Year Change||-36.24%|
|3 Year Change||34.13%|
|5 Year Change||157.16%|
|Change since IPO||2,482.36%|
Recent News & Updates
Medifast, Inc. (NYSE:MED) Analysts Are Reducing Their Forecasts For This Year
Today is shaping up negative for Medifast, Inc. ( NYSE:MED ) shareholders, with the analysts delivering a substantial...
|MED||US Personal Products||US Market|
Return vs Industry: MED underperformed the US Personal Products industry which returned -16.3% over the past year.
Return vs Market: MED underperformed the US Market which returned -8.9% over the past year.
|MED Average Weekly Movement||7.5%|
|Personal Products Industry Average Movement||10.6%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: MED is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: MED's weekly volatility (8%) has been stable over the past year.
About the Company
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform.
Medifast Fundamentals Summary
|MED fundamental statistics|
Is MED overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MED income statement (TTM)|
|Cost of Revenue||US$452.85m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||14.32|
|Net Profit Margin||9.44%|
How did MED perform over the long term?See historical performance and comparison
4.6%Current Dividend Yield
Is MED undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MED?
Other financial metrics that can be useful for relative valuation.
|What is MED's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does MED's PE Ratio compare to its peers?
|MED PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ELF e.l.f. Beauty
USNA USANA Health Sciences
IPAR Inter Parfums
NUS Nu Skin Enterprises
Price-To-Earnings vs Peers: MED is good value based on its Price-To-Earnings Ratio (9.9x) compared to the peer average (33.4x).
Price to Earnings Ratio vs Industry
How does MED's PE Ratio compare vs other companies in the US Personal Products Industry?
Price-To-Earnings vs Industry: MED is good value based on its Price-To-Earnings Ratio (9.9x) compared to the US Personal Products industry average (19.8x)
Price to Earnings Ratio vs Fair Ratio
What is MED's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||9.9x|
|Fair PE Ratio||18.7x|
Price-To-Earnings vs Fair Ratio: MED is good value based on its Price-To-Earnings Ratio (9.9x) compared to the estimated Fair Price-To-Earnings Ratio (18.7x).
Share Price vs Fair Value
What is the Fair Price of MED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MED ($142.03) is trading below our estimate of fair value ($159.4)
Significantly Below Fair Value: MED is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Medifast forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MED's forecast earnings growth (1.8% per year) is below the savings rate (1.9%).
Earnings vs Market: MED's earnings (1.8% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: MED's earnings are forecast to grow, but not significantly.
Revenue vs Market: MED's revenue (2% per year) is forecast to grow slower than the US market (7.9% per year).
High Growth Revenue: MED's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MED's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Medifast performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MED has high quality earnings.
Growing Profit Margin: MED's current net profit margins (9.4%) are lower than last year (11.8%).
Past Earnings Growth Analysis
Earnings Trend: MED's earnings have grown significantly by 35.5% per year over the past 5 years.
Accelerating Growth: MED's earnings growth over the past year (4.3%) is below its 5-year average (35.5% per year).
Earnings vs Industry: MED earnings growth over the past year (4.3%) underperformed the Personal Products industry 4.3%.
Return on Equity
High ROE: MED's Return on Equity (121.2%) is considered outstanding.
Discover strong past performing companies
How is Medifast's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MED's short term assets ($243.3M) exceed its short term liabilities ($188.2M).
Long Term Liabilities: MED's short term assets ($243.3M) exceed its long term liabilities ($22.9M).
Debt to Equity History and Analysis
Debt Level: MED has more cash than its total debt.
Reducing Debt: Insufficient data to determine if MED's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: MED's debt is well covered by operating cash flow (354.7%).
Interest Coverage: MED's interest payments on its debt are well covered by EBIT (462x coverage).
Discover healthy companies
What is Medifast current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MED's dividend (4.62%) is higher than the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: MED's dividend (4.62%) is in the top 25% of dividend payers in the US market (3.95%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, MED has been paying a dividend for less than 10 years.
Growing Dividend: MED's dividend payments have increased, but the company has only paid a dividend for 6 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (45.1%), MED's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (105.8%), MED's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Chard (57 yo)
Mr. Daniel R. Chard, also known as Dan, has been Chief Executive Officer of Medifast, Inc. since October 3, 2016 and Director since October 3, 2016 and also serves as its Executive Chairman since December...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD6.93M) is about average for companies of similar size in the US market ($USD5.43M).
Compensation vs Earnings: Dan's compensation has increased by more than 20% in the past year.
Experienced Management: MED's management team is considered experienced (3.2 years average tenure).
Experienced Board: MED's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MED insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medifast, Inc.'s employee growth, exchange listings and data sources
- Name: Medifast, Inc.
- Ticker: MED
- Exchange: NYSE
- Founded: 1980
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: US$1.556b
- Shares outstanding: 10.96m
- Website: https://medifastinc.com
Number of Employees
- Medifast, Inc.
- 100 International Drive
- 18th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.